Shareholders in AstraZeneca have voted to approve an 11% increase in the salary and bonus package for chief executive Pascal Soriot, although a sizeable minority did not approve.
All told, 78% of votes cast at the group’s annual meeting yesterday were in favour of raising Soriot’s remuneration to a maximum of £18.7 million ($23.4 million) from £16.9 million last year, despite objections from Glass Lewis and ISS, who provide proxy advisory services to institutional investors.
